Showing 381-390 of 404 results for "".
- Revance Appoints Brand Strategist Jill Beraud to Board of Directorshttps://modernaesthetics.com/news/revance-appoints-brand-strategist-jill-beraud-to-board-of-directors/2471899/Jill Beraud is now a member of Revance Therapeutics, Inc.'s Board of Directors. Ms. Beraud brings more than 25 years’ experience building luxury, fashion, beauty, and consumer brands. Ms. Beraud will also chair a newly-formed Revance Brand St
- Sciton Introduces JOULE X at ASLMShttps://modernaesthetics.com/news/sciton-introduces-joule-x-at-aslms/2471929/Sciton Inc. unveiled JOULE X and other new offerings at the annual American Society for Laser Medicine and Surgery Meeting in Denver, Colorado. An upgrade to the JOULE platform, JOULE X is the company’s latest multi-device platform. It works
- ASPS 2018 Data: Plastic Surgery is on the Rise and It's All About the Bodyhttps://modernaesthetics.com/news/asps-2018-data-plastic-surgery-is-on-the-rise-and-its-all-about-the-body/2471942/It’s official. Plastic surgery is on the rise. There were nearly 18 million more cosmetic procedures performed in 2018 than 2017, and this number has risen steadily over the past five years, according to the 2018 statistics from the
- Botox's New “Own Your Look" Campaign Targets Millennialshttps://modernaesthetics.com/news/botoxs-new-own-your-look-campaign-targets-millennials/2471957/Allergan’s new direct-to-consumer campaign, "Own Your Look," aims to address the most common misconceptions around Botox Cosmetic (onabotulinumtoxinA) among millennials, namely the fear of looking frozen. This is the first campaign from the brand created specifically to ad
- Leadership Change at Cutera; Preliminary Financial Results for 2018https://modernaesthetics.com/news/leadership-change-at-cutera-preliminary-financial-results-for-2018/2471966/Cutera has announced the resignation of James Reinstein as President, Chief Executive Officer and member of its Board of Directors, effective immediately. The Board has appointed Cutera’s Chief Operating Officer, Jason Richey, as Interim CEO. J. Daniel Plants, Chairman of Cutera, sa
- FDA Green Light's Galderma's Restylane Lyft for Midface Injection Via Cannulahttps://modernaesthetics.com/news/fda-green-lights-galdermas-restylane-lyft-for-midface-injection-via-cannula/2471998/The U.S. Food and Drug Administration (FDA) has approved the use of Galderma’s Restylane Lyft with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. This approval is the
- Recros Medica Unveils the Nuvellus Brand for Its Novel Rotational Fractional Resection Technologyhttps://modernaesthetics.com/news/recros-medica-unveils-the-nuvellus-brand-for-its-novel-rotational-fractional-resection-technology/2472023/Recros Medica, Inc. is unveiling the Nuvellus brand at this week’s American Society of Plastic Surgery meeting. The company will display at booth #1264, where it will introduce Nuvellus as an innovative, minimally-invasive surgical procedure in develop
- Galderma Launches "Face Your Hands" Campaign with Celebrity Manicuristhttps://modernaesthetics.com/news/galderma-launches-face-your-hands-campaign-with-celebrity-manicurist/2472030/Galderma Laboratories, L.P.,’s Restylane® Lyft is partnering with celebrity manicurist Deborah Lippmann for the "Face Your Hands" campaign, which aims to educate women on the steps they can take to achieve more youthful hands. A
- Cynosure to Distribute Porter Instrument's Nitrous Oxide and Oxygen System in Aesthetics Markethttps://modernaesthetics.com/news/cynosure-to-distribute-porter-instruments-nitrous-oxide-and-oxygen-system-in-aesthetics-market/2472047/Hologic, Inc.'s Cynosure division has penned a deal with Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to Porter Instrument&#
- Bonti's Novel Neurotoxin Shows Promise in Early Study of Scar Reduction After Mohs Surgeryhttps://modernaesthetics.com/news/bontis-novel-neurotoxin-shows-promise-in-early-study-of-scar-reduction-after-mohs-surgery/2472052/Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical